Last reviewed · How we verify
Fluticasone Furoate (FF)
Fluticasone furoate is a corticosteroid that binds to glucocorticoid receptors in the lungs to reduce inflammation and suppress immune responses in respiratory tissues.
Fluticasone furoate is a corticosteroid that binds to glucocorticoid receptors in the lungs to reduce inflammation and suppress immune responses in respiratory tissues. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD), Allergic rhinitis.
At a glance
| Generic name | Fluticasone Furoate (FF) |
|---|---|
| Also known as | fluticasone furoate, fluticasone propionate, Veramyst |
| Sponsor | GlaxoSmithKline |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
As a selective glucocorticoid receptor agonist, fluticasone furoate enters airway cells and binds intracellular glucocorticoid receptors, leading to transrepression of pro-inflammatory genes and reduced production of cytokines, chemokines, and adhesion molecules. This results in decreased airway inflammation, mucus production, and bronchial hyperresponsiveness. The furoate ester formulation provides enhanced potency and prolonged local activity compared to the parent fluticasone propionate.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
- Allergic rhinitis
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Nervousness
Key clinical trials
- Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma (PHASE4)
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
- To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD (PHASE4)
- A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma (PHASE3)
- 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation (PHASE4)
- Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma (PHASE3)
- Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma (PHASE3)
- Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone Furoate (FF) CI brief — competitive landscape report
- Fluticasone Furoate (FF) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI